Partnership to Improve Patient Care

  • Home
  • About
    • Mission and Priorities
    • Meet the Chairman
    • Steering Committee
    • PIPC Member List
    • Contact
  • The Issues
    • Value Our Health
    • International
    • Where We Stand
    • Value Assessment Frameworks
    • Engaging Patients in Value-Based Payment
    • Patient-Centeredness in Research
  • Resources
    • Advocacy
    • Letters and Comments
    • PCORI Meeting Transcripts
    • Polling
    • Roundtables
    • White Papers
  • Blog
    • PIPC Patients' Blog
    • Chairman's Corner
    • PIPC Weekly Update
    • The Data Mine
  • Newsroom
    • PIPC in the News
    • Press Releases
    • Open Letter: We Deserve a Voice
  • Events
    • PIPC Forum 2022
    • Discrimination & Health Care
    • C & GT Webinar
    • ICER COVID Webinar
    • Value Our Health Briefing
    • QALY Briefing
    • QALY Panel
    • Past Webinars >
      • ICER SCD Webinar
      • VOH Sickle Cell Webinar
      • Rare Disease Webinar
      • QALY Webinar
      • PCORI Advocacy Webinar
      • APM Webinar
      • Patient Empowerment Webinar
      • Value Assessments Briefing
    • Past PIPC Forums >
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010
  • Home
  • About
    • Mission and Priorities
    • Meet the Chairman
    • Steering Committee
    • PIPC Member List
    • Contact
  • The Issues
    • Value Our Health
    • International
    • Where We Stand
    • Value Assessment Frameworks
    • Engaging Patients in Value-Based Payment
    • Patient-Centeredness in Research
  • Resources
    • Advocacy
    • Letters and Comments
    • PCORI Meeting Transcripts
    • Polling
    • Roundtables
    • White Papers
  • Blog
    • PIPC Patients' Blog
    • Chairman's Corner
    • PIPC Weekly Update
    • The Data Mine
  • Newsroom
    • PIPC in the News
    • Press Releases
    • Open Letter: We Deserve a Voice
  • Events
    • PIPC Forum 2022
    • Discrimination & Health Care
    • C & GT Webinar
    • ICER COVID Webinar
    • Value Our Health Briefing
    • QALY Briefing
    • QALY Panel
    • Past Webinars >
      • ICER SCD Webinar
      • VOH Sickle Cell Webinar
      • Rare Disease Webinar
      • QALY Webinar
      • PCORI Advocacy Webinar
      • APM Webinar
      • Patient Empowerment Webinar
      • Value Assessments Briefing
    • Past PIPC Forums >
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010

The PIPC Blog

PIPC Patient Blog: Our Children Are Worth It

7/17/2018

 
Picture
This post was originally published as a July 17, 2018 article in Disabled World.

By: Stephanie Bozarth 

​
Should one consider the life of a person with a disability less valuable than the life of a person without a disability? Alarmingly, states are increasingly relying on policies that do just that, in order to determine the value of health care services and treatments. For children suffering from life-threatening and debilitating disorders, like my daughter, reliance on any standard that considers her life less valuable than someone without a disability, is simply unacceptable.

For example, starting this year, New York State's Drug Utilization Review Board used measurement of costs per quality-adjusted-life-years (QALYs) to assess the value of treatments to Medicaid beneficiaries. Also, Massachusetts sought a Medicaid waiver (currently under review) to exclude certain drugs from coverage based on a "cost effectiveness" calculation. For the first time, the federal government is seriously considering state proposals to use average "cost effectiveness" to limit formularies under Medicaid.

This recent trend is not the first instance of states attempting to use cost effectiveness data to limit or justify limiting patient access.

When Oregon received a Medicaid waiver in 1993 to establish the Prioritized Health Services List of covered services for its citizens on Medicaid, they quickly moved to reduce access to treatments for ultra-rare disorders, including MPS, Gaucher disease and Fabry disease among others, in part justifying its decisions using QALY-based cost effectiveness analysis. The blowback from patients and people with disabilities was swift who contend that QALYs fail to capture the value of a therapy to each individual patient. Many stakeholders contended the use of QALYs to determine care covered for patients with ultra-rare disorders is not only inappropriate, but discriminatory.

As the mother of a 12-year-old daughter with MPS, I can't help but get the shivers when new policies come out that could discriminate against children with disabilities. My daughter Annabelle has big blue eyes and a smile from ear-to-ear that lights up a room. She has hopes and dreams that are as big and exciting as any other young, vibrant child. But Annabelle's daily life is dramatically different than what the average American faces. Along with all the regular stresses of school, peer relations, and so forth, Annabelle is short in stature (approximately the size of a 3- or 4-year-old), she has severe bone and joint problems, hearing loss, corneal clouding, leaking heart valve, lower airway obstruction, along with other aches, pains and difficult-to-manage medical issues.

Through all of it, Annabelle is joyful and living a life with less pain and more stamina - thanks in large part to an FDA-approved orphan drug. To be sure, bypassing hurdles to get access to this product were in no way an easy feat. But this was one mountain well worth the climb because it gave Annabelle a new lease on a less painful and longer life. Each week, Annabelle has a 6-hour infusion of this life-improving medicine. It isn't a cure but what it is... is critically important.

Within months of starting this treatment, 5-year-old Annabelle was able to walk longer distances to the playground, climb up ladders, and "be a child" more often with less overall pain. She went from sitting on the park bench with big tears in her eyes to joining in with the rest of the kids. She can't do anything close to what those other kids can do but she is at least able to try. No academic cost effectiveness study captures the value of Annabelle's smile.

As Americans, we hold ourselves to a higher standard than just average.

We place value on all individuals and enforce laws to make sure those values are upheld and honored. If there was a medicine that gave a significantly improved quality of life to a small number of patients, don't those patients have equal value as the ones that have less complex or better understood diseases? Does the value of a patient's life reduce because it is harder and more expensive to treat? If it is your child or loved one, the answer is a no-brainer.

Wading into the waters of whether a patient is worth a treatment is dangerous territory.
​
One day, that may directly impact you or your loved one. When I watch my daughter walking rather than riding in a wheelchair and enjoying after-school activities like drama or coding club rather than being exhausted and isolated because of pain and exhaustion, the answer is very clear to me that she is worth it. She is living her best life because she has access to a treatment that is genuinely improving her quality of life. And I can only hope for the same for other kids just like Annabelle.
patient_blog_july_17_2018.pdf
File Size: 133 kb
File Type: pdf
Download File


Comments are closed.

    Topics

    All
    Alternative Payment Models
    Chairman's Corner
    Patient Centered Research
    PIPC In The News
    PIPC Patient Blog
    PIPC Weekly Update
    Press Releases
    The Data Mine
    Value Frameworks

    Archives

    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    April 2013
    March 2013
    December 2012
    November 2012
    February 2012
    September 2011
    August 2011
    July 2011
    May 2011
    March 2011
    November 2010
    October 2010
    September 2010
    August 2010
    April 2010
    March 2010
    February 2010
    December 2009
    September 2009
    July 2009
    June 2009
    May 2009
    February 2009
    January 2009
    December 2008

About PIPC
The Issues
Resources
Blog
In the News
Press Releases
Contact Us
100 M Street, SE – Ste. 750
Washington, DC 20003